Goodwin Procter·PHARMA / BIOTECH

Takeda Sues Alvotech Over Vedolizumab Biosimilar

In its second recent suit defending ENTYVIO®, Takeda alleges Alvotech's proposed vedolizumab biosimilar infringes six patents covering methods of treatment.

bpciabiosimilarspatent-litigationpharmatakedaalvotechvedolizumab

Read the original firm alert → Friday, September 4, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.